Israel’s BiolineRX has announced positive results for the Phase IIa clinical trial of BL-7040, an oral treatment for inflammatory bowel disease (IBD). Ulcerative colitis and Crohn’s disease affect as many as 1.4 million individuals in the US alone. http://www.globes.co.il/serveen/globes/docview.asp?did=1000836889&fid=1725

Israel’s BiolineRX has reported positive results in the preclinical trial of BL-7010, its treatment for celiac disease. The study found that BL-7010 was safe and reduces digestion of wheat gluten, thereby decreasing its toxicity. Currently, there is no cure or … Continue reading →

One of Israel’s NASDAQ listed bio-techs BiolineRX Ltd. reported positive results for its Phase Ia clinical trial of its drug, BL-1021, for the treatment of chronic neuropathic pain due to damaged nerves. It is associated with conditions including shingles, diabetes … Continue reading →